By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Goldman Sachs on Tuesday downgraded Cepheid shares to "Neutral" from "Buy," citing the stock's outperformance compared to its peer group and a less attractive risk/reward at current levels.

In a research note, Issac Ro noted strong performance by Cepheid's stock and expected continued growth at the company, but expressed concern over its high price-to-sales multiple of 7.4 times, compared to a median of 2.6 times for its peer group.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.